Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

As of November 30, 2017

188 joint negotiations have been **completed**** for the following drugs and indications:

Drug Product Brand Name (Generic Name)	Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria
Abilify Maintena (aripiprazole long acting injection)	Used for the maintenance treatment of schizophrenia
Abraxane (nab-paclitaxel)	Used first-line to treat locally advanced unresectable or metastatic adenocarcinoma of the pancreas
Actemra (tocilizumab) SC	Used to treat rheumatoid arthritis
Adcetris (brentuximab)	Used to treat lymphoma
Adempas (riociguat)	Used to treat chronic thromboembolic pulmonary hypertension
Advair (salmeterol xinafoate/ fluticasone propionate)	Used to treat chronic obstructive pulmonary disease and asthma
Afinitor (everolimus)	Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer
Afinitor (everolimus) ***	Used to treat neuroendocrine tumours of gastrointestinal or lung origin
Alimta (pemetrexed)	Used to treat lung cancer (new indication)
Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate)	Used to treat chronic obstructive pulmonary disease
Aptiom (eslicarbazepine)	Used to treat seizures
Arnuity Ellipta (fluticasone furoate)	Used to treat asthma
Aubagio (teriflunomide)	Used to treat relapsing-remitting multiple sclerosis
Avastin (bevacizumab)	Used to treat persistent, recurrent, or metastatic cervical cancer Used to treat epithelial ovarian cancer
Avastin (bevacizumab)	Used to treat genitourinary platinum-resistant ovarian cancer
Avastin (bevacizumab)	Used to treat metastatic colorectal cancer
Basaglar (insulin glargine)	Used to treat type 1 and 2 diabetes mellitus
Blincyto (blinatumomab)	Used to treat acute lymphoblastic leukemia
Bosulif (bosutinib)	Used to treat chronic myelogenous leukemia (CML)
Brenzys (etanercept)	Used to treat rheumatoid arthritis and ankylosing spondylitis
Breo Ellipta (fluticasone furoate/vilanterol)	Used for the treatment of asthma
Breo Ellipta (fluticasone furoate/vilanterol)	Used to treat chronic obstructive pulmonary disease
Brilinta (ticagrelor) [†]	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome
Cimzia (certolizumab)	Used to treat ankylosing spondylitis, psoriatic arthritis
Consentyx (secukinumab)	Used to treat moderate to severe plaque psoriasis
Cotellic (cobimetinib)	Used to treat metastatic melanoma
Cyramza (ramucirumab)	Used to treat gastrointestinal metastatic gastric cancer or gastro- esophageal junction adenocarcinoma
Daklinza (daclatasvir)	Used to treat chronic Hepatitis C infection
Diacomit (stiripentol)	Used in patients with severe myoclonic epilepsy in infancy
Dificid (fidaxomicin)	Used to treat Clostridium difficile
Duaklir Genuair (aclidinium bromide/formoterol fumarate dehydrate)	Used to treat chronic obstructive pulmonary disease (COPD)
Effient (prasugrel)	Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome

Drug Product Brand Name (Generic Name)	Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria
Eliquis (apixaban)	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Eliquis (apixaban)	Used to treat venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism
Entresto (sacubitril/valsartan)	Used to treat heart failure
Entyvio (vedolizumab)	Used to treat ulcerative colitis
Entyvio (vedolizumab)	Used to treat Crohn's disease
Epclusa (sofosbuvir/velpatasvir)	Used to treat chronic hepatitis C infection
Erelzi (etanercept)	Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis
Erivedge (vismodegib)	Used to treat metastatic basal cell carcinoma
Esbriet (pirfenidone)	Used to treat idiopathic pulmonary fibrosis
Esbriet (pirfenidone) (second letter of intent)	Used to treat idiopathic pulmonary fibrosis
Eylea (aflibercept)	Used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and/or macular edema secondary to central retinal vein occlusion (CRVO)
Eylea (aflibercept)	Used to treat macular edema secondary to branch retinal vein occlusion
Fabrazyme (agalsidase beta)	Used to treat Fabry disease
Fabrazyme (agalsidase beta) (second letter of intent)	Used to treat Fabry disease
Ferriprox (deferiprone)	Used to treat Transfusional Iron Overload
Fibristal (ulipristal acetate)	Used to treat uterine fibroids
Firazyr (icatibant)	Used to treat acute attacks of hereditary angioedema
Forxiga (dapagliflozin)	Used to treat Type 2 diabetes
Galexos (simeprevir)	Used to treat chronic hepatitis C Genotype 1 infection
Gazyva (obinutuzumab)	Used to treat chronic lymphocytic leukemia
Genvoya (elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide)	Used to treat HIV-1 Infection
Gilenya (fingolimod) [†]	Used to treat relapsing-remitting multiple sclerosis
Giotrif (afatinib)	Used to treat advanced non-small cell lung cancer
Giotrif (afatinib)* (second letter of intent)	Used to treat advanced non-small cell lung cancer
Grastofil (filgrastim)	Used for prevention or treatment of neutropenia in various indications
Halaven (eribulin)	Used to treat breast cancer
Harvoni (sofosbuvir/ledipsavir)	Used to treat chronic hepatitis C infection
Harvoni (sofosbuvir/ledipsavir) (second letter of intent)	Used to treat chronic hepatitis C infection
Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir)	Used to treat chronic hepatitis C infection
Humira (adalimumab)	Used to treat ulcerative colitis
Humira (adalimumab)	Used to treat hidradenitis suppurativa
Ibavyr (ribavirin)	Used to treat chronic hepatitis C infection
Iclusig (ponatinib)	Used to treat Chronic Myeloid Leukemia (CML)/ Acute Lymphoblastic Leukemia
Imbruvica (ibrutinib)	Used to treat chronic lymphocytic leukemia or small lymphocytic leukemia
Imbruvica (ibrutinib)	Used to treat relapsed/refractory Mantle Cell Lymphoma

Drug Product Brand Name (Generic Name)	Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria
Imbruvica (ibrutinib)	Used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma
Incruse Ellipta (umeclidinium)	Used to treat chronic obstructive pulmonary disease (COPD)
Inflectra (infliximab)	Used to treat rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis
Inflectra (infliximab)	Used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and Ulcerative Colitis
Inlyta (axitinib)	Used to treat metastatic renal cell carcinoma
Inspiolto Respimat (tiotropium/olodaterol)	Used to treat chronic obstructive pulmonary disease (COPD)
Inspra (eplerenone)	Used to treat New York Heart Association (NYHA) class II systolic heart failure
Invokana (canagliflozin)	Used to treat Type 2 diabetes
Istodax (romidepsin)	Used to treat relapsed/refractory peripheral T-cell lymphoma
Jadenu (deferasirox)	Used to treat chronic iron overload
Jakavi (ruxolitinib)	Used to treat intermediate to high risk myelofibrosis
Jakavi (ruxolitinib)	Used to treat polycythemia vera
Janumet (sitagliptin/metformin)	Used to treat Type 2 diabetes mellitus
Januvia (sitagliptin)	Used to treat Type 2 diabetes mellitus
Jardiance (empagliflozin)	Used to treat Type 2 diabetes mellitus
Jetrea (ocriplasmin)	Used to treat symptomatic vitreomacular adhesion
Kadcyla (trastuzumab emtansine)	Used to treat HER-2 positive metastatic breast cancer
Kalydeco (ivacaftor)	Used to treat cystic fibrosis
Keytruda (pembrolizumab)	Used to treat metastatic melanoma
Keytruda (pembrolizumab)*	Used to treat non-small cell lung cancer (second line or beyond)
Keytruda (pembrolizumab)*	Used to treat non-small cell lung cancer (first line)
Kuvan (saproterin) [†]	Used to treat phenylketonuria
Lemtrada (alemtuzumab)	Used to treat relapsing-remitting multiple sclerosis
Lenvima (lenvatinib)	Used to treat thyroid cancer
Lodalis (colesevelam)	Used to treat hypercholesterolemia
Mekinist (trametinib)	Used to treat metastatic melanoma
Metadol-D (methadone hydrochloride)	Used to treat opioid dependence
Metoject (methotrexate)*	Used to treat rheumatoid arthritis
Mifegymiso (mifepristone/misoprostol)	Used for the medical termination of pregnancy
Mozobil (plerixafor)	Used in combination with <i>granulocyte colony-stimulating factor</i> to support treatment for non-Hodgkin lymphoma and multiple myeloma
Mozobil (plerixafor) (second letter of intent)	Used in combination with granulocyte colony-stimulating factor to
Myrbetriq (mirabegron)	support treatment for non-Hodgkin lymphoma and multiple myelomaUsed to treat overactive bladder
Neupro (rotigotine)	Used to treat Parkinson's disease
Nucala (mepolizumab)*	Used to treat severe eosinophilic asthma
Ofev (nintedanib)	Used to treat idiopathic pulmonary fibrosis
Onbrez (indacaterol) [†]	Used as a bronchodilator for chronic obstructive pulmonary disease
Onglyza (saxagliptan)	Used to treat Type 2 diabetes mellitus
Opdivo (nivolumab)	Used to treat advanced or metastatic non-small cell lung cancer
Opdivo (nivolumab)	Used to treat metastatic melanoma

Drug Product Brand Name (Generic Name)	Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria
Opdivo (nivolumab)	Used to treat advanced or metastatic renal cell carcinoma
Opdivo (nivolumab)*	Used to treat squamous cell carcinoma of the head and neck (SCCHN)
Oralair (grass pollen allergen extract)	Used to treat allergic rhinitis with or without conjunctivitis
Orencia (abatacept)	Used to treat rheumatoid arthritis
Perjeta (pertuzumab)	Used to treat breast cancer
Pheburane (sodium phenylbutyrate)*	Used to treat urea cycle disorders
Plegridy (PegIFN beta-1a)	Used to treat relapsing-remitting multiple sclerosis (RRMS)
Pomalyst (pomalidomide)	Used to treat multiple myeloma
Pradaxa (dabigatran) [†]	Used to prevent strokes in patients with atrial fibrillation
Prezcobix (darunavir/cobicistat)	Used to treat HIV-1 infection
Prolia (denosumab)	Used to treat osteoporosis
Rebif (interferon beta-1a)	Used for clinically isolated syndrome
Remicade (infliximab)	Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn's disease
Repatha (evolocumab)	Used to treat primary hyperlipidemia and mixed dyslipidemia
Replagal (agalsidase alfa)	Used to treat Fabry Disease
Replagal (agalsidase alfa) (second letter of intent)	Used to treat Fabry Disease
Revlimid (lenalidomide)	Used for maintenance treatment in multiple myeloma after a stem cell transplant
Revlimid (lenalidomide)	Used to treat newly diagnosed multiple myeloma
Rituxan SC (rituximab)	Used to treat multiple indications
Seebri Breezhaler (glycopyrronium bromide)	Used to treat chronic obstructive pulmonary disease
Simbrinza (brinzolamide/brimonidine)	Used to treat glaucoma and ocular hypertension
Simponi (golimumab) SC	Used to treat ulcerative colitis
Soliris (eculizumab) [†]	Used to treat paroxysmal nocturnal hemoglobinuria
Sovaldi (sofosbuvir)	Used to treat chronic hepatitis C infection
Sovaldi (sofosbuvir) (second letter of intent)	Used to treat chronic hepatitis C infection
Spiriva Respimat (tiotropium)	Used to treat chronic obstructive pulmonary disease
Stivarga (regorafenib)	Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST)
Stivarga (regorafenib)* (second letter of intent)	Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST)
Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir)	Used to treat HIV-1 infection in antiretroviral treatment-naïve adult patients
Sunvepra (asunaprevir)	Used to treat chronic Hepatitis C
Sutent (sunitinib)	Used to treat pancreatic neuroendocrine tumours
Sylvant (siltuximab)	Used to treat multicentric Castleman's disease
Tafinlar (darafenib)	Used to treat metastatic melanoma
Tafinlar (dabrafenib) and Mekinist (tramatinib)	Used to treat metastatic melanoma (in combination)
Tecfidera (dimethyl fumarate)	Used to treat multiple sclerosis
Tivicay (dolutegravir)	Used to treat HIV-1 infection
Tobi Podhaler (tobramycin)	Used for the management of cystic fibrosis patients with chronic pulmonary <i>Pseuodomonas aeruginosa</i> infections
Tradjenta (linagliptin) and Jentadueto	Used to treat Type 2 diabetes mellitus

Drug Product Brand Name (Generic Name)	Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria
(linagliptin/metformin)	
Treanda (bendamustine) [†]	Used to treat non-Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia
Triumeq (dolutegravir/abacavir/lamivudine)	Used to treat HIV-1 infection
Tudorza Genuair (aclidinium bromide)	Used in management of chronic obstructive pulmonary disease (COPD)
Tysabri (natalizumab)	Used to treat relapsing-remitting multiple sclerosis
Ultibro (indacaterol/glycopyrronium)	Used to treat chronic obstructive pulmonary disease
Valtrex (valacyclovir)	Used to treat specific viral infections
Vectibix (panitumumab)	Used to treat metastatic colorectal cancer
Votrient (pazopanib)	Used to treat metastatic renal cell carcinoma
Votrient (pazopanib) (second letter of intent)	Used to treat metastatic renal cell carcinoma
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer (second-line)
Xalkori (crizotinib)	Used to treat advanced non-small cell lung cancer (first-line)
Xarelto (rivaroxaban)	New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism.
Xarelto (rivaroxaban) [†]	Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis
Xeljanz (tofacitinib)	Used to treat rheumatoid arthritis
XigDuo (dapagliflozin/metformin hydrochloride)	Used to treat type 2 diabetes mellitus
Xolair (omalizumab)	Used to treat chronic idiopathic urticaria
Xtandi (enzalutamide)	Used to treat first-line metastatic castrate resistant prostate cancer (before chemotherapy)
Xtandi (enzulatamide)	Used to treat castrate resistant prostate cancer (after chemotherapy)
Yervoy (ipilimumab)	Used for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Yervoy (ipilimumab) [†]	Used for the second-line treatment of adult patients with unresectable or metastatic melanoma
Zaxine (rifaximin)	Used to treat hepatic encephalopathy
Zepatier (elbasvir grazoprevir)	Used for the treatment of Hepatitis C (genotype 1, 4)
Zydelig (idelalisib)	Used to treat relapsed chronic lymphocytic leukemia (CLL)
Zytiga (abiraterone)	Used to treat prostate cancer

20 drug negotiations were closed as agreements were not reached:	
Abilify (aripiprazole)	Used for the treatment of schizophrenia and related psychotic disorders
Adempas (riociguat)	Used to treat pulmonary arterial hypertension
Brilinta (ticagrelor)*	Used with ASA to prevent atherothrombotic events with history of myocardial infarction
Butrans (buprenorphine)	Used to treat persistent pain of moderate intensity
Byetta (exenatide)	Used to treat Type 2 diabetes
Campral (acamprosate calcium)	Used for maintenance of alcohol abstinence
Caprelsa (vandetanib)	Used to treat medullary thyroid cancer
Daklinza (daclatasvir)	Used to treat chronic Hepatitis C
Invokamet (canagliflozin/metformin	Used to treat type 2 diabetes mellitus

hydrochloride)	
Kalydeco (ivacaftor)	Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation
Kevzara (sarilumab)	Used to treat rheumatoid arthritis
Methadose (methadone)*	Used to treat opioid dependence
Opsumit (macitentan)	Used to treat pulmonary arterial hypertension
Otezla (apremilast)	Used to treat moderate to severe plaque psoriasis
Rosiver (ivermectin)	Used to treat rosacea
Simponi (golimumab) IV	Used to treat rheumatoid arthritis
Soliris (eculizumab)	Used to treat aHUS
Strensiq (asfotase alfa)	Used to treat hypophosphatasia
Technivie (ombitasvir/paritaprevir/ ritonavir)	Used for the treatment of Hepatitis C (genotype 4)
Victoza (liraglutide)	Used to treat Type 2 diabetes

** A completed pan-Canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer OR negotiations have been closed without a Letter of Intent.

*** Please note that this negotiation was completed in September 2017.

[†]The initial nine products negotiated through the pCPA.

* New negotiations completed since last update of October 31, 2017.